NCT04577001View on ClinicalTrials.gov

Letrozole in Patients With Hepatopulmonary Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 18, 2021

Primary Completion Date

March 26, 2021

Study Completion Date

March 26, 2021

Conditions
Hepatopulmonary Syndrome
Interventions
DRUG

Letrozole

2.5 mg orally daily for 6 months

DRUG

Placebo

No active ingredient taken orally daily for 6 months

Trial Locations (1)

55902

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

lead

Mayo Clinic

OTHER

NCT04577001 - Letrozole in Patients With Hepatopulmonary Syndrome | Biotech Hunter | Biotech Hunter